Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways

Synapse

Volumn 39, Issue 2, 2001, Pages 152-160

  Sakai, Kazuo ^a   Gao, Xue Min ^a   Hashimoto, Takeshi ^a   Tamminga, Carol A ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Antipsychotic drugs; Chronic drug treatment; Dopamine receptors; Enkephalin mRNA; GABA receptors; GAD67 mRNA; Haloperidol; Olanzapine; Rats; Schizophrenia; Sertindole; Substance P mRNA; Tardive dyskinesia; VCM

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ENKEPHALIN; HALOPERIDOL; MESSENGER RNA; NEUROLEPTIC AGENT; OLANZAPINE; SERTINDOLE; SUBSTANCE P;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; GABAERGIC TRANSMISSION; LATERAL RETICULAR NUCLEUS; MALE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT; RECEPTOR UPREGULATION; THALAMOCORTICAL TRACT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; CORPUS STRIATUM; DOWN-REGULATION; HALOPERIDOL; IMIDAZOLES; INDOLES; MALE; NEUROTRANSMITTER AGENTS; PIRENZEPINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; THALAMUS; UP-REGULATION;

EID: 0035136421     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2396(200102)39:2<152::AID-SYN6>3.0.CO;2-F     Document Type: Article

References (55)

1. 1 receptors and stimulation of striatal cholinergic interneurons by dopamine: A proposed circuit mechanism
2. Functional architecture of basal ganglia circuits: Neural substrates of parallel processing [Review]
3. Parallel organization of functionally segregated circuits linking basal ganglia and cortex [Review]
4. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics
5. Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial
6. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial
7. Radioreceptor binding profile of the atypical antipsychotic olanzapine
8. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinson's disease
9. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain
10. Schizophrenia
11. Pharmacological characterization of tardive dyskinesia
12. Comparative distribution of mRNAs for glutamic acid decarboxylase, tyrosine hydroxylase, and tachykinins in the basal ganglia: An in situ hybridization study in the rodent brain
13. Changes in cerebral dopamine metabolism and receptors during one-year neuroleptic administration and subsequent withdrawal: Relevance to brain biochemistry in schizophrenia
14. Changes in cerebral dopamine function induced by a year's administration of trifluoperazine or thioridazine and their subsequent withdrawal
15. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
16. 2 dopamine receptors in the human brain
17. Primate models of movement disorders of basal ganglia origin
18. 2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias
19. Effects of rating parameters on assessment of neuroleptic-induced vacuous chewing movements
20. Pharmacologic and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol
21. Tremorous mouth movements in rats administered chronic neuroleptics
22. Two genes encode distinct glutamate decarboxylases
23. Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain
24. Chronic blockade of dopamine receptors by antischizophrenic drugs enhances GABA binding in substantia nigra
25. Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol
26. Phencyclidine (PCP) and dizocilpine (MK801) exert time-dependent effects on the expression of immediate early genes in rat brain
27. Intermittent neuroleptic treatment induces long-lasting abnormal mouthing in the rat
28. Understanding manic-depressive illness
29. Neurotransmitters and neuromodulators in the basal ganglia
30. Reductions of nigral glutamic acid decarboxylase in rats with neuroleptic-induced oral dyskinesia
31. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis
32. Biochemistry of somatodendritic dopamine release in substantia nigra: An in vivo comparison with striatal dopamine release
33. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol
34. Three rat preprotachykinin mRNAs encode the neuropeptides substance P and neurokinin A
35. Modulation of oral movements by intranigral 5-hydroxytryptamine receptor agonists in the rat
36. Are thalamocortical rhythms the Rosetta Stone of a subset of neurological disorders?
37. 3H] muscimol binding in rat brain
38. Effects of olanzapine on regional C-Fos expression in rat forebrain
39. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity
40. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound
41. 1, receptors after long-term haloperidol treatment: Lack of correspondence with the development of vacuous chewing movements
42. Dopamine receptor pharmacology [Review]
43. Brain receptors for antipsychotic drugs and dopamine: Direct binding assays
44. Basal ganglia GABAA and dopamine D1 binding site correlates of haloperidol-induced oral dyskinesias in rat
45. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurons in rats: Acute and repeated treatment
46. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat
47. Effects of subthalamic nucleus lesions in a putative model of tardive dyskinesia in the rat
48. Improvement in tardive dyskinesia after muscimol therapy
49. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: A study in three rat strains
50. Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment
51. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
52. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: Phenomenology, pathophysiology and putative relationship to tardive dyskinesia
53. Rat brain preproenkephalin mRNA. cDNA cloning, primary structure, and distribution in the central nervous system
54. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia